Equities analysts expect Synthetic Biologics, Inc (NASDAQ:SYN) to report earnings per share of ($0.64) for the current quarter, Zacks reports. Zero analysts have provided estimates for Synthetic Biologics’ earnings. Synthetic Biologics posted earnings per share of ($0.70) during the same quarter last year, which would suggest a positive year over year growth rate of 8.6%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Synthetic Biologics will report full-year earnings of ($2.48) per share for the current financial year. For the next year, analysts forecast that the firm will post earnings of ($2.54) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Synthetic Biologics.
Separately, William Blair reaffirmed an “outperform” rating on shares of Synthetic Biologics in a research note on Thursday, February 28th.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Featured Article: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.